Michael Heller,
Professor, Dept Bioengineering,
University of California-San Diego
Michael J. Heller received his PhD in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanogen and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller is a Professor (Recall/Emeritus) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has also co-founded a company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, electrokinetic lab-on-a-chip devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanostructures. Dr. Heller has over 100 publications and 56 issued US patents.
Isolation and Analysis of DNA/RNA Biomarkers from Hematological Cancer, Solid Tumors and TBI Patient Samples
Tuesday, 29 September 2015 at 17:30
Add to Calendar ▼2015-09-29 17:30:002015-09-29 18:30:00Europe/LondonIsolation and Analysis of DNA/RNA Biomarkers from Hematological Cancer, Solid Tumors and TBI Patient SamplesNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Rapid isolation and fluorescent detection of ccf-DNA/RNA biomarkers from CLL, solid tumor and TBI patient samples (20-100ul) is achieved in 10-15 minutes using an AC dielectrophoretic (DEP) microarray device. In the case of chronic lymphocytic leukemia (CLL), both PCR and DNA sequencing analysis for CLL derived ccf-DNA produces analytical results comparable to conventional “gold standard” procedures. Now, in order to determine the origin of ccf-DNA fragments, apoptotic ~180bp or necrotic >180bp, or both, PCR based amplicon size analysis and sequencing is being carried out on ccf-DNA isolated by DEP from CLL and solid tumor (lung, breast, colon) samples. For CLL, 540 bp mutation-containing PCR amplicons are readily produced even from low levels of ccf-DNA isolated by DEP from both blood and plasma samples suggesting a necrotic origin. Identification of the size range of ccf-DNA cancer biomarkers for their apoptotic or necrotic origins may very well have its own diagnostic value. Ultimately, DEP based sample to answer microarray systems will enable liquid biopsy for cancer and other molecular diagnostic point of care (POC) applications.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonNGS, SCA, Mass Spec: The Road to DiagnosticsNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-29 17:30:002015-09-29 18:30:00Europe/LondonIsolation and Analysis of DNA/RNA Biomarkers from Hematological Cancer, Solid Tumors and TBI Patient SamplesNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
